Skip to main content

Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF
1 in progress, 1 open to new patients

  • Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

    open to eligible females ages 18 years and up

    This is a pilot study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.

    San Francisco, California